New drug targets rare lung cancer mutation
NCT ID NCT04036682
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called CLN-081 in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). Participants must have already received chemotherapy. The goal is to see if the drug is safe and can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CLN-081 (zipalertinib)
- What this could lead to
- If successful, this could provide a new targeted treatment option for people with a hard-to-treat form of lung cancer.
- What could go wrong
- This is an early-phase trial, so the drug may not work as hoped or could cause significant side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR EXON 20 MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth
Orlando, Florida, 32804, United States
-
Ajou University Hospital
Suwon, South Korea
-
Asan Medical Center (AMC)
Soeul, South Korea
-
Azienda Ospedaliero Universitaria Careggi
Careggi, Italy
-
Azienda Ospedaliero Universitaria Modena
Modena, Italy
-
Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I
Marche, Italy
-
Chang Gung Medical Foundation Chiayi Chang Gung Memorial Hospital
Chiayi City, Taiwan
-
Chung Shan Medical University Hospital
Taichung, Taiwan
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
-
Clinica Universidad de Navarra
Pamplona, Spain
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Complejo Hospitalario Universitario Insular Materno Infantil
Las Palmas, Spain
-
Gabrail Cancer Center Research
Canton, Ohio, 44701, United States
-
Gachon University Gil Medical Center
Incheon, South Korea
-
Hong Kong University - Queen Mary Hospital
Hong Kong, Hong Kong
-
Hospital Clinic i Provincial de Barcelona
Barcelona, Spain
-
Hospital General Universitario Gregorio Maranon (HGUGM)
Madrid, Spain
-
Hospital Parc Tauli
Barcelona, Spain
-
Hospital Regional Universitario de Malaga
Málaga, Spain
-
Hospital Universitario Puerta de Hierro de Majadahonda
Madrid, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, Spain
-
IRCCS-Istituto Europeo di Oncologia
Milan, Italy
-
Inha University Hospital
Incheon, South Korea
-
Institut Catala d'Oncologia l'Hospitalet
Barcelona, Spain
-
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
Meldola, Italy
-
Korea University Guro Hospital
Soeul, South Korea
-
Leiden University Medical Center
Leiden, 2333 ZA, Netherlands
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center
Goyang-si, South Korea
-
National Cancer Center Hospital
Tokyo, Japan
-
National Cancer Center Hospital East
Chiba, Japan
-
National Cancer Centre Singapore
Singapore, 169610, Singapore
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
New York University Langone Health
New York, New York, 10016, United States
-
Niigata Cancer Center
Niigata, Japan
-
Osaka City General Hospital
Osaka, Japan
-
Osaka International Cancer Institute
Osaka, Japan
-
Ospedale Santa Maria delle Croci
Ravenna, Italy
-
Pacific Cancer Medical Center, Inc
Anaheim, California, 92801, United States
-
Pacific Shores Medical Group
Long Beach, California, 90813, United States
-
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York, 11501, United States
-
Providence Cancer Center
Portland, Oregon, 97213, United States
-
Providence Oncology & Hematology Care Clinic-Westside
Portland, Oregon, 97225, United States
-
START Barcelona
Barcelona, Spain
-
Samsung Medical Center
Seoul, South Korea
-
San Gerardo Hospital
Monza, Italy
-
Seoul National University Bundang Hospital (SNUBH)
Gyeonggi-do, South Korea
-
Shizuoka Cancer Center
Shizuoka, Japan
-
Singapore Clinical Research Institute
Singapore, 138669, Singapore
-
Summit Medical Group PA
Florham Park, New Jersey, 07932, United States
-
Taichung Veterans General Hospital
Taichung, Taiwan
-
Taipei Medical University Hospital
Taipei, Taiwan
-
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Tokyo, Japan
-
The Catholic University Of Korea St. Vincent's Hospital
Suwon, South Korea
-
The Netherlands Cancer Institute (NKI)
Amsterdam, 1066 CX, Netherlands
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur)
Valencia, Spain
-
University Hospital A Coruna
A Coruña, Spain
-
University Hospital Quironsalud Madrid
Madrid, Spain
-
University of Michigan Health System - University Hospital
Ann Arbor, Michigan, 48109, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?